IL6 and adult-onset Still disease: The situation is even more challenging for AOSD, since adults are only granted access when they fail to respond to two sDMARDs (16), despite Nordström et al. demonstrating the superior beneficial effect of IL-1 blockade compared to sDMARD in an open, randomised, multi-centre study (19), and proven benefits of IL-6 blockade for both joint disease and systemic features in AOSD (20, 21).